PA
XPRO icon

PharVision Advisers’s Expro Ltd XPRO Stock Holding History

PharVision Advisers’s Portfolio XPRO Stock Details XPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,775
Closed -$152K – 1041
2025
Q3 		$152K Buy
+12,775
New +$139K 0.09% 570

Other funds holding XPRO

OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

PharVision Advisers's XPRO Position: Q4 2025 in Review

PharVision Advisers sold out of Expro Ltd (XPRO) in Q4 2025, closing a stake of 12,775 shares — an estimated $152K sold.

PharVision Advisers first reported a position in XPRO in Q3 2025 and held it in 1 quarter. The position peaked at $152K in Q3 2025. 193 funds tracked by Wall St. Rank hold XPRO as of Q4 2025.

  • PharVision Advisers reported no remaining Expro Ltd position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 12,775 Expro Ltd shares in Q4 2025, an estimated $152K.
  • PharVision Advisers first reported a position in Expro Ltd in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Expro Ltd position peaked at $152K in Q3 2025.
  • 193 funds tracked by Wall St. Rank held Expro Ltd as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.